At a Glance
- Company: GSK plc
- Location: London HQ; US approval
- Label change: Now adults 18–49 at increased RSV risk
- Focus area: Prevention of RSV lower respiratory tract disease
- Next steps: US uptake in risk groups, further global filings
What happened?
The US Food and Drug Administration has expanded the approved age indication for GSK’s RSV vaccine Arexvy to include adults aged 18–49 years who are at increased risk of lower respiratory tract disease caused by RSV. Arexvy was previously limited to adults 60 and older, and to at‑risk adults aged 50–59, so the decision substantially widens its on‑label use.
Why does it matter?
GSK estimates about 21 million US adults under 50 have at least one risk factor for severe RSV disease, creating a significantly larger addressable market for Arexvy. The decision also marks a regulatory win in a period when vaccine policy and demand have been choppy, potentially helping stabilise GSK’s RSV franchise and intensifying competition with Pfizer’s Abrysvo and Moderna’s mRESVIA in younger at‑risk adults.
Who’s behind it?
Arexvy is developed and marketed by GSK, which was first to secure an RSV vaccine approval in older adults and has built a leading share in the emerging RSV market. The company’s vaccines leadership has framed the expanded label as part of a broader strategy to bring RSV prevention to more adult populations at higher medical risk.
How was it achieved?
The label expansion is supported by a Phase IIIb immunogenicity trial in adults 18–49 with stable chronic conditions that increase RSV risk, showing a non‑inferior immune response versus adults 60 and older and a safety profile consistent with earlier Phase III data. Arexvy uses a prefusion RSV F protein antigen combined with GSK’s AS01E adjuvant to boost immune responses against RSV‑A and RSV‑B.
What’s next?
GSK plans to leverage the broader US label in discussions with advisers and payers to drive uptake in eligible high‑risk adults under 50, while continuing regulatory submissions in other geographies to sustain long‑term RSV growth. Market focus will now shift to real‑world use, guideline updates, and how strongly prescribers prioritise RSV vaccination in younger adults with chronic diseases.
What are people saying?
GSK’s head of vaccines and infectious diseases R&D said the age expansion helps address a significant unmet need in high‑risk younger adults and may ease pressure on healthcare systems during RSV seasons. Analysts note that while vaccine policy remains politically sensitive, the broader label gives GSK a clearer commercial path in RSV despite recent volatility in vaccine demand.